Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $23.00 million. The enterprise value is $58.92 million.
Important Dates
The next confirmed earnings date is Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 44.53 million shares outstanding. The number of shares has increased by 2.04% in one year.
| Current Share Class | 44.53M |
| Shares Outstanding | 44.53M |
| Shares Change (YoY) | +2.04% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 7.76% |
| Owned by Institutions (%) | 36.09% |
| Float | 33.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 4.92 |
| PS Ratio | 0.26 |
| Forward PS | 0.25 |
| PB Ratio | 1.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.75 |
| P/OCF Ratio | 3.47 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 16.65, with an EV/FCF ratio of 12.17.
| EV / Earnings | n/a |
| EV / Sales | 0.66 |
| EV / EBITDA | 16.65 |
| EV / EBIT | n/a |
| EV / FCF | 12.17 |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of 2.76.
| Current Ratio | 0.81 |
| Quick Ratio | 0.35 |
| Debt / Equity | 2.76 |
| Debt / EBITDA | 7.51 |
| Debt / FCF | 8.96 |
| Interest Coverage | -1.00 |
Financial Efficiency
Return on equity (ROE) is -138.36% and return on invested capital (ROIC) is -2.46%.
| Return on Equity (ROE) | -138.36% |
| Return on Assets (ROA) | -1.98% |
| Return on Invested Capital (ROIC) | -2.46% |
| Return on Capital Employed (ROCE) | -13.29% |
| Revenue Per Employee | $250,000 |
| Profits Per Employee | -$161,707 |
| Employee Count | 355 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 1.61 |
Taxes
In the past 12 months, HBIO has paid $457,000 in taxes.
| Income Tax | 457,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.91% in the last 52 weeks. The beta is 1.52, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | -78.91% |
| 50-Day Moving Average | 0.45 |
| 200-Day Moving Average | 0.62 |
| Relative Strength Index (RSI) | 58.74 |
| Average Volume (20 Days) | 17,423,667 |
Short Selling Information
The latest short interest is 579,892, so 1.30% of the outstanding shares have been sold short.
| Short Interest | 579,892 |
| Short Previous Month | 681,364 |
| Short % of Shares Out | 1.30% |
| Short % of Float | 1.73% |
| Short Ratio (days to cover) | 0.56 |
Income Statement
In the last 12 months, HBIO had revenue of $88.75 million and -$57.41 million in losses. Loss per share was -$1.31.
| Revenue | 88.75M |
| Gross Profit | 50.54M |
| Operating Income | -3.31M |
| Pretax Income | -56.95M |
| Net Income | -57.41M |
| EBITDA | 3.54M |
| EBIT | -3.31M |
| Loss Per Share | -$1.31 |
Full Income StatementBalance Sheet
The company has $7.44 million in cash and $43.36 million in debt, giving a net cash position of -$35.92 million or -$0.81 per share.
| Cash & Cash Equivalents | 7.44M |
| Total Debt | 43.36M |
| Net Cash | -35.92M |
| Net Cash Per Share | -$0.81 |
| Equity (Book Value) | 15.73M |
| Book Value Per Share | 0.35 |
| Working Capital | -10.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.62 million and capital expenditures -$1.78 million, giving a free cash flow of $4.84 million.
| Operating Cash Flow | 6.62M |
| Capital Expenditures | -1.78M |
| Free Cash Flow | 4.84M |
| FCF Per Share | $0.11 |
Full Cash Flow StatementMargins
Gross margin is 56.94%, with operating and profit margins of -3.73% and -64.68%.
| Gross Margin | 56.94% |
| Operating Margin | -3.73% |
| Pretax Margin | -64.17% |
| Profit Margin | -64.68% |
| EBITDA Margin | 3.99% |
| EBIT Margin | -3.73% |
| FCF Margin | 5.45% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.04% |
| Shareholder Yield | -2.04% |
| Earnings Yield | -249.54% |
| FCF Yield | 21.04% |
Analyst Forecast
The average price target for HBIO is $2.50, which is 383.93% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.50 |
| Price Target Difference | 383.93% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HBIO has an Altman Z-Score of -2.15 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.15 |
| Piotroski F-Score | 4 |
